Sylvain C.
- Country
- France
- Department
- Hematology
Research Overview
- Phase 2 Open-Label Study of Brentuximab Vedotin and CHP in Frontline Treatment of Peripheral T-Cell Lymphoma with <10% CD30 Expression
- Efficacy and Safety of Golcadomide with R-CHOP Versus Placebo with R-CHOP in High-risk Large B-cell Lymphoma: A Phase 3 Randomized Controlled Trial
- Phase II Evaluation of Ibrutinib and Rituximab in Treatment-Naïve CD20-Positive Marginal Zone B-Cell Lymphoma Patients Requiring Systemic Therapy
Data & Insights
Has run more than one trial at 130 of 299 partner sites.
Specializations
T-Cell Lymphoma Research
Specializes in investigating treatments for peripheral T-cell lymphoma (PTCL), with particular focus on novel therapeutic combinations including KIR3DL2-positive PTCL subtypes.
- PTCL-NOS and PTCL-TFH variants
- ALCL and ATL lymphomas
- Histiocytic and NK/T-cell lymphomas
Explores innovative treatment approaches using targeted therapies in combination with conventional chemotherapy regimens.
B-Cell Lymphoma Studies
Focuses on advancing treatment options for large B-cell lymphoma and follicular lymphoma, particularly in high-risk and relapsed/refractory cases.
- High-risk aggressive B-cell lymphomas
- Post-CAR T-cell therapy interventions
- Novel immunotherapy combinations
Investigates innovative therapeutic strategies including immunomodulatory compounds and targeted treatments.
Marginal Zone Lymphoma Expertise
Specializes in treating marginal zone lymphoma variants, with emphasis on both splenic and other subtypes through innovative therapeutic approaches.
- Splenic marginal zone lymphoma
- Relapsed/refractory disease management
- Combination immunotherapy strategies
Evaluates novel treatment combinations incorporating targeted therapies with established immunotherapeutic agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.